naive B cell

**Development (bone marrow):** Pro-B → pre-B → immature B → transitional B → mature naive B. Key steps: heavy chain VDJ recombination (RAG1/RAG2, TdT) → pre-B receptor (μ heavy chain + surrogate light chain) → light chain VJ recombination (κ before λ) → surface IgM on immature B cell. Allelic exclusion ensures each B cell expresses one heavy and one light chain allele. Immature B cells with strong self-reactivity undergo central tolerance: receptor editing (preferred), clonal deletion (apoptosis), or anergy. Surviving cells leave as transitional B cells and complete maturation in the spleen, where they co-express IgM and IgD through alternative splicing of a long primary transcript. Both isotypes share the same antigen specificity.

**Phenotype:** Surface IgM + IgD (BCR), CD19, CD20, CD21 (CR2, also the EBV receptor), MHC II, and CD40. BCR signaling uses the Igα/Igβ (CD79a/b) heterodimer, and the CD19/CD21/CD81 complex acts as a co-receptor. They have not undergone somatic hypermutation or class switching, and they have low-affinity BCRs. They express CD27 negative (memory B cells are CD27+).

**Activation (peripheral lymphoid organs):** 1. Antigen binds the BCR and is internalized, processed, and presented on MHC II. 2. Helper T cell (Th2/Tfh) recognizes the peptide-MHC II via TCR, and CD40L (T cell) engages CD40 (B cell) to give the second signal. Cytokines (IL-4, IL-5, IL-6, IL-21) support the response. 3. Activated B cells enter the germinal center, where they undergo: - **Somatic hypermutation** and **affinity maturation** (AID, activation-induced cytidine deaminase) - **Class switching** (AID; cytokine-directed, e.g., IL-4 → IgE/IgG4, IFN-γ → IgG, TGF-β → IgA) 4. Results in long-lived **plasma cells** (secrete antibody) and **memory B cells**.

**T-independent activation:** Naive B cells (especially marginal zone and B-1 cells) can respond to polysaccharide or repetitive antigens with BCR cross-linking, but no T-cell help. This produces mostly IgM, with no class switching, no strong memory, and a poor response in young children (<2 years). This is the rationale for conjugate vaccines (polysaccharide + protein carrier, e.g., Hib, pneumococcal, meningococcal), which recruit T cell help.

**Clinical correlations:** - **X-linked (Bruton) agammaglobulinemia:** BTK mutation blocks the pro-B → pre-B transition (pre-BCR signaling). Result: no mature or naive B cells, low CD19+ cells in blood, absent lymph node germinal centers and tonsils, and low Ig of all classes. Recurrent encapsulated bacterial infections begin after ~6 months, when maternal IgG wanes. - **Hyper-IgM syndrome:** Defective CD40L (X-linked) or AID causes failure of class switching. Naive B cells are present, but IgM is high and IgG, IgA, and IgE are low. Opportunistic infections (e.g., Pneumocystis) occur with CD40L deficiency. - **SCID (RAG, Artemis defects):** No VDJ recombination, so no mature B or T cells. - **CVID:** Normal B cell numbers but impaired differentiation to plasma cells; low IgG/IgA. - **Lymphomas:** Origin often correlates with stage of B cell differentiation. Mantle cell lymphoma (t(11;14), cyclin D1) arises from naive B cells in the mantle zone (CD5+, CD20+). CLL/SLL is CD5+/CD23+ B cells. Lymphomas of germinal center origin (follicular t(14;18) BCL2, Burkitt t(8;14) MYC, DLBCL) arise after antigen exposure and show somatic hypermutation. - **Rituximab (anti-CD20)** depletes naive and memory B cells but not pro-B cells or plasma cells (CD20-negative), which is why Ig levels are relatively preserved.

**High-yield distinctions:** - Naive B: IgM/IgD, no SHM, not antigen-experienced. - Memory B: class-switched (IgG/IgA/IgE), SHM, higher affinity, CD27+, faster and stronger secondary response. - Plasma cell: secretes antibody, with low surface Ig and CD20, and high CD38/CD138. - Primary response (naive B cells): lag of ~7–10 days, IgM first. Secondary response (memory B cells): rapid, IgG-predominant, higher affinity.